A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

Based on data from the BEACON and NAUTICAL studies, regulatory authorities greenlit the combo for later-line patients.

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

NEW YORK – RedHill Biopharma has begun recruiting patients with metastatic castration-resistant prostate cancer to a Phase II trial testing the combination of opaganib, its small molecule sphingosine ...

Zegfrovy's approval offers this subset of advanced NSCLC patients their first oral targeted treatment option.

The funds will help the firm advance copper-based radioligand therapies and imaging agents in prostate, neuroendocrine, and breast cancers.

NEW YORK – A new law in Texas could pave the way for more community cancer practices to provide CAR T-cell therapy. At least that's the goal, according to Brooks Landgraf, a Republican representative ...

NEW YORK – Iksuda Therapeutics sees an opportunity to help patients who have relapsed on AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) by using a novel HER2-targeted antibody-drug ...

NEW YORK – 4D Molecular Therapeutics on Wednesday said it will reduce its workforce by 25 percent, cutting primarily early-stage R&D and support functions. The layoffs are part of the Emeryville, ...